Announcements Trials
Browse Landscape

Phase

Phase 2 30Phase 3 3Phase NA 2Phase 4 2Phase 2/3 2Phase EARLY_PHASE1 1Phase 1/2 1Phase 1 1

Status

Unknown 10Completed 4Not yet recruiting 3Terminated 2Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Craniopharyngioma 1

Interventions

pembrolizumab 109Cyclophosphamide 85fludarabine 67Carboplatin 59Injections 58Bevacizumab 52Specimen Handling 42Gemcitabine 41Paclitaxel 40Magnetic Resonance Spectroscopy 40venetoclax 38Nivolumab 38Cisplatin 37Dexamethasone 35Biopsy 34Temozolomide 31Docetaxel 29atezolizumab 27Oxaliplatin 26Capecitabine 26Pemetrexed 25Fluorouracil 25toripalimab 24abemaciclib 24Irinotecan 24Azacitidine 24Fulvestrant 23Rituximab 21fludarabine phosphate 20durvalumab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Recruiting × anlotinib × Clear all
NCT06970145 2025-11-18

Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma

Nanfang Hospital, Southern Medical University

Phase 1/2 Recruiting
57 enrolled
CNS

Craniopharyngioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡